Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles | Zendy

Jan Tesařík | Zendy; A. Hazout | Zendy; Raquel MendozaTesarik | Zendy; Nicolás Mendoza | Zendy; C. Mendoza | Zendy

Open Access

Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles

Author(s) -

Jan Tesařík,

A. Hazout,

Raquel MendozaTesarik,

Nicolás Mendoza,

C. Mendoza

Publication year - 2006

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/del173

Subject(s) - agonist , luteal phase , triptorelin , medicine , endocrinology , gonadotropin releasing hormone , buserelin , gonadotropin releasing hormone antagonist , corpus luteum , stimulation , andrology , ovary , luteinizing hormone , hormone , receptor

GnRH agonist was recently suggested as a novel luteal-phase support that may act at different levels, including the pituitary gonadotrophs, the endometrium and the embryo itself. This prospective randomized study evaluates the effect of GnRH agonist administered in the luteal phase on ICSI outcomes in both GnRH agonist- and GnRH antagonist-treated ovarian stimulation protocols.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research